Pharma BD Deal Intelligence
Haisco Pharmaceutical Group granted Sentivera, a newly formed U.S. venture founded by Population Health Partners and ARCH Venture Partners, exclusive global rights (excluding Greater China) to develop, manufacture and commercialise a preclinical immunology asset that inhibits the development and progression of type 2 inflammatory diseases. The asset is described by Haisco as a core immunology programme and received China IND approval in August 2026; the specific molecule name and mechanism of action were not disclosed. Consideration comprises an upfront payment plus equity in the new venture totalling USD 75.89 million, up to USD 1.46 billion in development, regulatory and commercial milestones, and tiered royalties from mid-single digits to low double digits on post-launch net sales. Rather than a conventional out-licence, the transaction is structured as a NewCo partnership in which Haisco retains an equity position in the vehicle developing the asset outside Greater China.
← Browse all deals · How we score deals
More: 2026 deals